$EVOK
Evoke Pharma Inc

2023 Q2 Form 10-Q Financial Statement

#000095017023022182 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $1.131M $810.4K $418.4K
YoY Change 144.99% 93.7% 362.7%
Cost Of Revenue $57.36K $50.59K $22.76K
YoY Change -15.36% 122.28% -62.07%
Gross Profit $1.074M $759.8K $395.6K
YoY Change 172.57% 92.06% 1218.73%
Gross Profit Margin 94.93% 93.76% 94.56%
Selling, General & Admin $2.766M $2.848M $2.405M
YoY Change 19.48% 18.41% 2.86%
% of Gross Profit 257.55% 374.82% 607.93%
Research & Development $92.36K $66.99K $41.72K
YoY Change -51.77% 60.58% -84.98%
% of Gross Profit 8.6% 8.82% 10.54%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.916M $2.966M $2.470M
YoY Change 13.26% 20.08% -7.88%
Operating Profit -$1.784M -$2.155M -$2.051M
YoY Change -15.54% 5.07% -20.82%
Interest Expense $124.7K $123.3K -$122.5K
YoY Change 0.0% -200.65% -199.31%
% of Operating Profit
Other Income/Expense, Net -$83.49K -$87.96K $0.00
YoY Change -30.85% -100.0%
Pretax Income -$1.868M -$2.243M -$2.174M
YoY Change -16.36% 3.19% -16.72%
Income Tax
% Of Pretax Income
Net Earnings -$1.868M -$2.243M -$2.174M
YoY Change -16.36% 3.19% -16.57%
Net Earnings / Revenue -165.1% -276.78% -519.54%
Basic Earnings Per Share -$0.56 -$0.67 -$0.80
Diluted Earnings Per Share -$0.56 -$0.67 -$795.8K
COMMON SHARES
Basic Shares Outstanding 3.343M 3.343M 2.731M
Diluted Shares Outstanding 3.343M 3.343M 2.731M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.006M $8.213M $7.701M
YoY Change -47.91% 6.64% -57.66%
Cash & Equivalents $7.000M $8.200M $7.700M
Short-Term Investments
Other Short-Term Assets $11.55K $11.55K $627.4K
YoY Change 0.0% -98.16% 1.19%
Inventory $513.7K $364.9K $278.8K
Prepaid Expenses $371.3K $671.4K
Receivables $1.024M $687.3K $418.9K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $8.927M $9.948M $9.026M
YoY Change -38.03% 10.21% -52.94%
LONG-TERM ASSETS
Property, Plant & Equipment $52.84K $91.40K $0.00
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $52.84K $91.40K $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $8.927M $9.948M $9.026M
Total Long-Term Assets $52.84K $91.40K $0.00
Total Assets $8.980M $10.04M $9.026M
YoY Change -37.66% 11.22% -53.22%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.415M $1.186M $944.5K
YoY Change 71.66% 25.56% 36.88%
Accrued Expenses $665.8K $491.7K $412.2K
YoY Change 25.93% 19.27% -25.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.081M $1.678M $1.357M
YoY Change 53.8% 23.65% -78.29%
LONG-TERM LIABILITIES
Long-Term Debt $5.000M $5.000M $5.000M
YoY Change 0.0% 0.0% 0.0%
Other Long-Term Liabilities $1.360M $1.236M $735.6K
YoY Change 58.12% 67.97% 206.49%
Total Long-Term Liabilities $6.360M $6.236M $5.736M
YoY Change 8.53% 8.72% 9.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.081M $1.678M $1.357M
Total Long-Term Liabilities $6.360M $6.236M $5.736M
Total Liabilities $8.441M $7.913M $7.092M
YoY Change 17.02% 11.57% -38.25%
SHAREHOLDERS EQUITY
Retained Earnings -$119.8M -$117.9M
YoY Change 7.09%
Common Stock $120.3M $120.0M
YoY Change 1.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $538.4K $2.126M $1.934M
YoY Change
Total Liabilities & Shareholders Equity $8.980M $10.04M $9.026M
YoY Change -37.66% 11.22% -53.22%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.868M -$2.243M -$2.174M
YoY Change -16.36% 3.19% -16.57%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.206M -$1.631M -$1.615M
YoY Change -12.18% 0.98% -45.31%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 171.5K
YoY Change -100.0% -98.69%
NET CHANGE
Cash From Operating Activities -1.206M -1.631M -1.615M
Cash From Investing Activities
Cash From Financing Activities 0.000 171.5K
Net Change In Cash -1.206M -1.631M -1.444M
YoY Change -120.98% 12.98% -114.27%
FREE CASH FLOW
Cash From Operating Activities -$1.206M -$1.631M -$1.615M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001403708
CY2023Q1 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36075
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
EVOKE PHARMA, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8447886
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
420 Stevens Avenue
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 370
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Solana Beach
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92075
CY2023Q1 dei City Area Code
CityAreaCode
858
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
345-1494
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2023Q1 dei Trading Symbol
TradingSymbol
EVOK
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3343070
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8212804
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9843699
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
687302
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
624832
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
671386
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
952954
CY2023Q1 us-gaap Inventory Net
InventoryNet
364867
CY2022Q4 us-gaap Inventory Net
InventoryNet
289378
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
11551
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
11551
CY2023Q1 us-gaap Assets Current
AssetsCurrent
9947910
CY2022Q4 us-gaap Assets Current
AssetsCurrent
11722414
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
91397
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
129074
CY2023Q1 us-gaap Assets
Assets
10039307
CY2022Q4 us-gaap Assets
Assets
11851488
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1185925
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
934312
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
400251
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
591158
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
91397
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
129074
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1677573
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1654544
CY2023Q1 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2022Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
5000000
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
1235583
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
1112295
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6235583
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
6112295
CY2023Q1 us-gaap Liabilities
Liabilities
7913156
CY2022Q4 us-gaap Liabilities
Liabilities
7766839
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3343070
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3343070
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3343070
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3343070
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
334
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
334
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
120016030
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
119731458
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-117890213
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-115647143
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2126151
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4084649
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10039307
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11851488
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
810408
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
418380
CY2023Q1 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
50591
CY2022Q1 evok Cost Of Goods Sold Expenses
CostOfGoodsSoldExpenses
22760
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
66990
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
41717
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2847940
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2405075
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2965521
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
2469552
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2155113
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2051172
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
35331
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
795
CY2023Q1 us-gaap Interest Expense
InterestExpense
123288
CY2022Q1 us-gaap Interest Expense
InterestExpense
123288
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-87957
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-122493
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2243070
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2173665
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.67
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.67
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.80
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3343070
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3343070
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2731440
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2731440
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4084649
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
284572
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2243070
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
2126151
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
3555094
CY2022Q1 evok Payment Of At Market Offering Costs
PaymentOfAtMarketOfferingCosts
3548
CY2022Q1 evok Issuance Of Common Stock From At The Market Offerings Value
IssuanceOfCommonStockFromAtTheMarketOfferingsValue
171521
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
381061
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2173665
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1934011
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2243070
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2173665
CY2023Q1 evok Non Cash Lease Expense
NonCashLeaseExpense
37676
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
284572
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
381061
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
62470
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
123717
CY2023Q1 evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-206079
CY2022Q1 evok Increase Decrease In Prepaid Deferred Expense Inventory And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseInventoryAndOtherAssets
-227100
CY2023Q1 evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
251613
CY2022Q1 evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
58022
CY2023Q1 evok Accrued Compensation
AccruedCompensation
190907
CY2022Q1 evok Accrued Compensation
AccruedCompensation
107119
CY2023Q1 evok Accrued Interest Expense
AccruedInterestExpense
123288
CY2022Q1 evok Accrued Interest Expense
AccruedInterestExpense
123288
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-37676
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1630895
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1615030
CY2022Q1 evok Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
175069
CY2022Q1 evok Payment Of Common Stock Offering Cost At Market Offering
PaymentOfCommonStockOfferingCostAtMarketOffering
3548
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
171521
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1630895
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1443509
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9843699
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9144710
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8212804
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7701201
CY2023Q1 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8200000
CY2022Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-12 reverse stock split
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q1 evok Bad Debt Expense
BadDebtExpense
0
CY2022Q1 evok Bad Debt Expense
BadDebtExpense
0
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
214000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
239000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
122000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
28000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
50000
CY2023Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2022-10-31
CY2023Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
94000
CY2023Q1 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P0Y6M29D
CY2023Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.10
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
40112
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
569351
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
452122
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
37281
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2017Q4 evok Common Stock Shares To Be Issued Value
CommonStockSharesToBeIssuedValue
16000000.0
CY2023Q1 evok Class Of Warrant Or Right Number Of Securities Expired
ClassOfWarrantOrRightNumberOfSecuritiesExpired
138972
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
284572
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
381061
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1800000
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y18D

Files In Submission

Name View Source Status
0000950170-23-022182-index-headers.html Edgar Link pending
0000950170-23-022182-index.html Edgar Link pending
0000950170-23-022182.txt Edgar Link pending
0000950170-23-022182-xbrl.zip Edgar Link pending
evok-20230331.htm Edgar Link pending
evok-20230331.xsd Edgar Link pending
evok-20230331_cal.xml Edgar Link unprocessable
evok-ex10_1.htm Edgar Link pending
evok-ex31_1.htm Edgar Link pending
evok-ex31_2.htm Edgar Link pending
evok-ex32_1.htm Edgar Link pending
evok-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img215256224_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
evok-20230331_def.xml Edgar Link unprocessable
evok-20230331_lab.xml Edgar Link unprocessable
evok-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
evok-20230331_htm.xml Edgar Link completed